European Journal of Epidemiology

, Volume 26, Issue 7, pp 511–525

Reliability of hypothalamic–pituitary–adrenal axis assessment methods for use in population-based studies

  • Sherita Hill Golden
  • Gary S. Wand
  • Saurabh Malhotra
  • Ihab Kamel
  • Karen Horton


Population-based studies have been hampered in exploring hypothalamic–pituitary–adrenal axis (HPA) activity as a potential explanatory link between stress-related and metabolic disorders due to their lack of incorporation of reliable measures of chronic cortisol exposure. The purpose of this review is to summarize current literature on the reliability of HPA axis measures and to discuss the feasibility of performing them in population-based studies. We identified articles through PubMed using search terms related to cortisol, HPA axis, adrenal imaging, and reliability. The diurnal salivary cortisol curve (generated from multiple salivary samples from awakening to midnight) and 11 p.m. salivary cortisol had the highest between-visit reliabilities (r = 0.63–0.84 and 0.78, respectively). The cortisol awakening response and dexamethasone-suppressed cortisol had the next highest between-visit reliabilities (r = 0.33–0.67 and 0.42–0.66, respectively). Based on our own data, the inter-reader reliability (rs) of adrenal gland volume from non-contrast CT was 0.67–0.71 for the left and 0.47–0.70 for the right adrenal glands. While a single 8 a.m. salivary cortisol is one of the easiest measures to perform, it had the lowest between-visit reliability (R = 0.18–0.47). Based on the current literature, use of sampling multiple salivary cortisol measures across the diurnal curve (with awakening cortisol), dexamethasone-suppressed cortisol, and adrenal gland volume are measures of HPA axis tone with similar between-visit reliabilities which likely reflect chronic cortisol burden and are feasible to perform in population-based studies.


Adrenal gland volume Cortisol awakening response Cortisol diurnal curve Dexamethasone suppression test Reliability Salivary cortisol 



Adrenocorticotrophic hormone


Atheroslerosis Risk In Communities Study


Area under the curve


Body mass index


Cortisol awakening response


Corticotrophin binding globulin


Corticotrophin releasing hormone


Computed tomography


Hypothalamic–pituitary–adrenal axis


Intraclass correlation coefficient


Multi-Ethnic Study Atherosclerosis


Magnetic resonance imaging


Pearson’s linear correlation coefficient


Spearman’s ordinal correlation coefficient


Urine free cortisol


  1. 1.
    McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87:873–904.PubMedCrossRefGoogle Scholar
  2. 2.
    Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev. 2010;35:2–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med. 2002;23:51–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Roux AV, Lee HB, Lyketsos C. Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008;299:2751–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Golden SH. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Curr Diabetes Rev. 2007;3:252–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Szklo M, Nieto FJ. Quality assurance and control. Epidemiology beyond the Basics. Sudbury: Jones and Bartlett Publishers; 2004. pp. 343–404.Google Scholar
  8. 8.
    Derr RL, Cameron SJ, Golden SH. Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research. Eur J Epidemiol. 2006;21:217–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Hellhammer DH, Wust S, Kudielka BM. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology. 2009;34:163–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Raff H. Utility of salivary cortisol measurements in Cushing’s syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3647–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Groschl M, Rauh M. Influence of commercial collection devices for saliva on the reliability of salivary steroids analysis. Steroids. 2006;71:1097–100.PubMedCrossRefGoogle Scholar
  12. 12.
    Garde AH, Hansen AM. Long-term stability of salivary cortisol. Scand J Clin Lab Invest. 2005;65:433–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Levine A, Zagoory-Sharon O, Feldman R, Lewis JG, Weller A. Measuring cortisol in human psychobiological studies. Physiol Behav. 2007;90:43–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Broderick JE, Arnold D, Kudielka BM, Kirschbaum C. Salivary cortisol sampling compliance: comparison of patients and healthy volunteers. Psychoneuroendocrinology. 2004;29:636–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Badrick E, Kirschbaum C, Kumari M. The relationship between smoking status and cortisol secretion. J Clin Endocrinol Metab. 2007;92:819–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Granger DA, Hibel LC, Fortunato CK, Kapelewski CH. Medication effects on salivary cortisol: tactics and strategy to minimize impact in behavioral and developmental science. Psychoneuroendocrinology. 2009;34:1437–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Coste J, Strauch G, Letrait M, Bertagna X. Reliability of hormonal levels for assessing the hypothalamic-pituitary-adrenocortical system in clinical pharmacology. Br J Clin Pharmacol. 1994;38:474–9.PubMedGoogle Scholar
  18. 18.
    Harris TO, Borsanyi S, Messari S, Stanford K, Cleary SE, Shiers HM, Brown GW, Herbert J. Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br J Psychiatr. 2000;177:505–10.CrossRefGoogle Scholar
  19. 19.
    Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab. 2005;90:5730–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri AM, Maffini MA, Scillitani A, Ambrosi B, Beck-Peccoz P, Chiodini I. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol. 2009;160:87–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Pruessner JC, Wolf OT, Hellhammer DH, Buske-Kirschbaum A, von Auer K, Jobst S, Kaspers F, Kirschbaum C. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997;61:2539–49.PubMedCrossRefGoogle Scholar
  22. 22.
    Edwards S, Clow A, Evans P, Hucklebridge F. Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. Life Sci. 2001;68:2093–103.PubMedCrossRefGoogle Scholar
  23. 23.
    Kraemer HC, Giese-Davis J, Yutsis M, O’Hara R, Neri E, Gallagher-Thompson D, Taylor CB, Spiegel D. Design decisions to optimize reliability of daytime cortisol slopes in an older population. Am J Geriatr Psychiatr. 2006;14:325–33.CrossRefGoogle Scholar
  24. 24.
    Ranjit N, Diez-Roux AV, Sanchez B, Seeman T, Shea S, Shrager S, Watson K. Association of salivary cortisol circadian pattern with cynical hostility: multi-ethnic study of atherosclerosis. Psychosom Med. 2009;71:748–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Hruschka DJ, Kohrt BA, Worthman CM. Estimating between- and within-individual variation in cortisol levels using multilevel models. Psychoneuroendocrinology. 2005;30:698–714.PubMedCrossRefGoogle Scholar
  26. 26.
    Knutsson U, Dahlgren J, Marcus C, Rosberg S, Bronnegard M, Stierna P, Albertsson-Wikland K. Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab. 1997;82:536–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Schmidt-Reinwald A, Pruessner JC, Hellhammer DH, Federenko I, Rohleder N, Schurmeyer TH, Kirschbaum C. The cortisol response to awakening in relation to different challenge tests and a 12-hour cortisol rhythm. Life Sci. 1999;64:1653–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–602.PubMedCrossRefGoogle Scholar
  29. 29.
    Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res. 1996;4:277–82.PubMedGoogle Scholar
  30. 30.
    Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab. 1998;83:47–54.PubMedCrossRefGoogle Scholar
  31. 31.
    Golden SH, Malhotra S, Wand GS, Brancati FL, Ford D, Horton K. Adrenal gland volume and dexamethasone-suppressed cortisol correlate with total daily salivary cortisol in African-American women. J Clin Endocrinol Metab. 2007;92:1358–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Yanovski SZ, Yanovski JA, Gwirtsman HE, Bernat A, Gold PW, Chrousos GP. Normal dexamethasone suppression in obese binge and nonbinge eaters with rapid weight loss. J Clin Endocrinol Metab. 1993;76:675–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Wingenfeld K, Lange W, Wulff H, Berea C, Beblo T, Saavedra AS, Mensebach C, Driessen M. Stability of the dexamethasone suppression test in borderline personality disorder with and without comorbid PTSD: a one-year follow-up study. J Clin Psychol. 2007;63:843–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Reynolds RM, Bendall HE, Whorwood CB, Wood PJ, Walker BR, Phillips DI. Reproducibility of the low dose dexamethasone suppression test: comparison between direct plasma and salivary cortisol assays. Clin Endocrinol (Oxf). 1998;49:307–10.CrossRefGoogle Scholar
  35. 35.
    Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic–pituitary–adrenal axis activity. Clin Endocrinol (Oxf). 2005;63:336–41.CrossRefGoogle Scholar
  36. 36.
    Harris B, Watkins S, Cook N, Walker RF, Read GF, Riad-Fahmy D. Comparisons of plasma and salivary cortisol determinations for the diagnostic efficacy of the dexamethasone suppression test. Biol Psychiatr. 1990;27:897–904.CrossRefGoogle Scholar
  37. 37.
    Imaki T, Naruse M, Takano K. Adrenocortical hyperplasia associated with ACTH-dependent Cushing’s syndrome: comparison of the size of adrenal glands with clinical and endocrinological data. Endocr J. 2004;51:89–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Rubin RT, Phillips JJ, Sadow TF, McCracken JT. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatr. 1995;52:213–8.PubMedGoogle Scholar
  39. 39.
    Cooper MS, Stewart PM. Diagnosis and treatment of ACTH deficiency. Rev Endocr Metab Disord. 2005;6:47–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Klose M, Lange M, Kosteljanetz M, Poulsgaard L, Feldt-Rasmussen U. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test. Clin Endocrinol (Oxf). 2005;63:499–505.CrossRefGoogle Scholar
  41. 41.
    Rubin RT, Phillips JJ, McCracken JT, Sadow TF. Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. Biol Psychiatr. 1996;40:89–97.CrossRefGoogle Scholar
  42. 42.
    Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatr Res. 1987;21:189–97.CrossRefGoogle Scholar
  43. 43.
    Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, Thanh PN, Gimm O, Spielmann RP, Dralle H. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J Surg. 2008;32:863–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Grant LA, Napolitano A, Miller S, Stephens K, McHugh SM, Dixon AK. A pilot study to assess the feasibility of measurement of adrenal gland volume by magnetic resonance imaging. Acta Radiol. 2010;51:117–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRefGoogle Scholar
  46. 46.
    Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatr. 1983;40:493–500.PubMedGoogle Scholar
  47. 47.
    Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord. 1982;4:93–101.PubMedCrossRefGoogle Scholar
  48. 48.
    Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res. 1994;28:341–56.PubMedCrossRefGoogle Scholar
  49. 49.
    Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M, Pfennig A, Ernst G, Kern N, Schmid DA, Uhr M, Holsboer F, Modell S. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology. 2003;28:2169–78.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Sherita Hill Golden
    • 1
    • 2
    • 5
  • Gary S. Wand
    • 1
  • Saurabh Malhotra
    • 4
  • Ihab Kamel
    • 3
  • Karen Horton
    • 3
  1. 1.Department of MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Department of EpidemiologyJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of RadiologyJohns Hopkins UniversityBaltimoreUSA
  4. 4.Department of MedicineIndiana University School of MedicineIndianapolisUSA
  5. 5.Division of Endocrinology and MetabolismJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations